Geovax next-generation covid-19 vaccine demonstrates potent antibody and cellular immunity in immunocompromised patients

Data published from phase 2 open-label study of geo-cm04s1 atlanta, ga, sept. 19, 2023 (globe newswire) -- via newmediawire – geovax labs, inc. (nasdaq: govx), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today the publication of data from the ongoing phase 2 trial of its next-generation covid-19 vaccine (geo-cm04s1) in the journal vaccines.
GOVX Ratings Summary
GOVX Quant Ranking